Drugs / GenSci140
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07251166 | Dec 2025 → Mar 2028 expected | cancer | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-27 | Changchun GeneScience Pharmaceutical Co., Ltd. | Results GenSci Presents Multiple Innovative Oncology Pipelines at AACR 2026 genscigroup.com ↗
Irrespective of FRα expression levels, GenSci140 exhibits significant antitumor efficacy and a favorable potential safety profile in various CDX and PDX models, including ovarian cancer models. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-27 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci Presents Multiple Innovative Oncology Pipelines at AACR 2026 genscigroup.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07251166 ↗ |